Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

ClinicalTrials.gov ID: NCT02441946

Public ClinicalTrials.gov record NCT02441946. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination With Anastrozole to Those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy With Abemaciclib in Combination With Anastrozole in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Study identification

NCT ID
NCT02441946
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
224 participants

Conditions and interventions

Interventions

  • Abemaciclib Drug
  • Anastrozole Drug
  • Loperamide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2015
Primary completion
Aug 15, 2016
Completion
Feb 11, 2018
Last update posted
Jun 16, 2020

2015 – 2018

United States locations

U.S. sites
27
U.S. states
14
U.S. cities
26
Facility City State ZIP Site status
Comprehensive Blood and Cancer Center Bakersfield California 93309
University of California-San Diego La Jolla California 92037-0845
SMO TRIO -Translational Research Los Angeles California 90024
UCLA Medical Center Los Angeles California 90024
Cancer Care Associates Medical Group Redondo Beach California 90277
Sansum Medical Research Foundation Santa Barbara California 93105
Central Coast Medical Oncology Corporation Santa Monica California 93454
Stanford University Stanford California 94305
SMO Pharmatech Oncology Inc Denver Colorado 80203
St Mary's Hospital Regional Cancer Center Grand Junction Colorado 81501
Holy Cross Hospital Inc. Fort Lauderdale Florida 33308
Memorial Regional Hospital/Joe Dimaggio Childrens Hospital Hollywood Florida 33021
Oncology and Radiation Associates Miami Florida 33133
Orlando Health, Inc Orlando Florida 32806
Florida Cancer Research Institute Plantation Florida 33324
Northeast Georgia Cancer Care, LLC Athens Georgia 30607
Georgia Regents University Augusta Georgia 30912
Kaiser Foundation Hospitals Honolulu Hawaii 96819
Walter Reed National Military Medical Center Bethesda Maryland 20889
University of Massachusetts Medical Center Worcester Massachusetts 80203
Nebraska Hematology-Oncology Lincoln Nebraska 68506
Weill Cornell Medical College New York New York 10021
St. Charles Health System Bend Oregon 97701
The West Clinic Germantown Tennessee 38138
Millennium Oncology Houston Texas 77090
Utah Cancer Specialists Salt Lake City Utah 84106
Columbia Basin Hematology & Oncology Kennewick Washington 99336

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02441946, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 16, 2020 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02441946 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →